Therapeutic peptides and diagnostic agents with their molecular size below the renal clearance threshold suffer from short blood circulation time. Here, we report a novel design of peptide-based ligand with a strong binding affinity to human serum albumin (HSA), which can be used as a tag to extend the blood circulation of small-size molecules. We designed ligands with dual alkyl groups connected with a negatively charged spacer. The ligands showed both higher binding affinity to HSA and a higher retention in mice blood than that of a single alkylated peptide.
Introduction
Strategies to improve the blood half-life of peptide drugs are highly demanded because they often display a half-life of a few minutes. Such strategies can minimize the dosage frequency of the peptide drugs. The conjugation of peptides to polyethylene glycol (PEG) has been used conventionally for this purpose. However, repeated administration of PEGylated peptides is known to be associated with immunogenicity against PEG, which reduces the half-life of PEGylated peptides. 1 Human serum albumin (HSA), the most abundant protein in the blood (0.6 mM), has a long serum half-life of 19 days. This long half-life is due to the avoidance of lysosomal degradation via the endocytic salvage pathway. 2, 3 HSA is the natural carrier for many exogenous and endogenous substances. 4 HSA has recently been utilized to improve the blood half-life of peptide drugs. 5, 6 As shown in Fig. 1A , HSA is composed of three homologous domains, I -III, and each one is divided into subdomains A and B. As HSA possesses seven hydrophobic pockets against relatively long fatty acids, [7] [8] [9] alkyl modification of peptide drugs enables reversible binding with HSA to enhance the blood half-life. Levemir, Degludec, and Victoza are based on a single alkylation on the peptide sequence of human insulin or glucagon-like-1. 10, 11 This modification has extended these therapeutic peptides half-life from few minutes to hours, and consequently reduced the dosage frequency. 5, 11, 12 However, generally, the binding affinity of alkylated peptides to HSA is attenuated by at least one order of magnitude compared with the original free fatty acid, probably due to an increase in the overall hydrophilicity of the fatty acid and/or steric repulsion associated with the rest of peptides. 10 Here, we propose a design of peptide-based ligands to HSA, in which two alkyl chains are introduced on to an appropriate spacer, expecting to enhance the binding affinity to HSA. Among the seven pockets of HSA against fatty acids, pockets 2, 4, and 5 are reported to be relatively strong. 8 As shown in Figs. 1B and 1C, combinations of pockets 4 and 6 or 4 and 5 are expected to be cross-linkable by two alkyl groups because their entrance confronts a same face of HSA with a similar close proximity (~2 nm). There is a cleft connecting two pockets in both combinations, which seems to be preferable to crosslink the pockets. Based on these structural features of HSA we designed four kinds of peptide-based ligands, shown in Fig. 2 . Here, we examined the binding affinity and the blood circulation property of the peptides to show the validity of the dual alkylation design for stronger binding to HSA.
Experimental

Reagents
NovaSyn TGA resin (amine density of 0.2 mmol/g), FmocGlu(Odmab)-OH, Fmoc-Asp(OtBu)-OH and Fmoc-Gly-OH were obtained from Novabiochem, Merck (Tokyo, Japan).
, and piperidine were purchased from Watanabe Chemical (Tokyo, Japan).
Pyridine, N,N-dimethyl-4-aminopyridine benzoic anhydride (DMAP) and N,N-diisopropylcarbodiimide (DIC) were obtained from Wako Pure Chemicals (Osaka, Japan). Boc-11-amino-3,6,9-trioxaundecanoic acid·DCHA (Boc-mini-PEG3) and Fmoc-11-3,6,9-trioxaundecanoic acid (Fmoc-mini-PEG3) were purchased from Peptides International (Kentucky, USA). N,N-Dimethylformamide (DMF) was purchased from Kanto Chemical (Tokyo, Japan). All reagents were used without further purification. Fatty acid free human serum albumin and myristic acid were purchased from Sigma-Aldrich. Tetradecylamine, hexadecylamine and sodium salt of 8-anilino-1-naphthalenesulfonate (ANS·Na) were purchased from Tokyo Chemical Industry (Tokyo, Japan).
Synthesis of peptide 1 -4, 1-Cy7, 2-Cy7
The peptides were synthesized manually by standard Fmoc chemistry using NovaSyn TGA resin (density of 0.2 mmol/g), DIEA as a base and COMU as coupling reagents. Deprotection of the N α -Fmoc was carried out in 20% piperidine/DMF, followed by washings with dichloromethane (DCM) and dimethylformamide (DMF). Modification of peptides with tetradecylamine or hexadecylamine were conducted after deprotection of Dmab group of Glu in two steps; treatment of the resin bound peptide with 2% hydrazine monohydrate in DMF for 30 min followed by treatment of the resin with 5 mM sodium hydroxide in 1:1 v/v of methanol/water incubated for 3 h. 13 After completion of the synthesis, the peptide was cleaved from the resin and was purified by reverse-phase liquid chromatography. The obtained peptides were identified by MALDI-TOF-MS. Cy7-modified peptides were synthesized by modifying sulfo-Cy7-NHS on the N-terminus of peptides 1 and 2 in DFM.
Fluorescence titrations
Stock solutions of 40 μM HSA and 100 μM ANS were prepared by dissolving HSA and ANS·Na, respectively, into 10 mM sodium phosphate buffer (pH 7.4). The HSA solution saturated with bound ANS (ANS/HSA complex) was prepared by mixing the HSA and ANS solutions with their final 
Animal experiments
Animal studies were performed in accordance with the Guidelines for Animal Care and Use Committee at Kyushu University (Fukuoka, Japan). Five-week-old ICR female mice (ca. 25 g) were injected intravenously through the tail with 2.1 nmol of 1-Cy7 and 2-Cy7 in PBS. At 6 h after injection, mice blood was collected in heparinized tubes by cardiac puncture under anesthesia. Plasma was obtained centrifuging the blood samples at 1200 × g for 10 min at 4 C. Fluorescence intensities of the retained peptides in the plasma were measured. Results are expressed as mean ± SD (n = 4).
Results and Discussion
We designed four kinds of peptides, shown in Fig. 2 . Peptides 1 and 3 have two alkyl groups (C14 or C16), which are connected with a linker possessing four ionizable carboxyl groups. These four carboxyl groups are expected to interact with cationic residues (Lys and Arg) existing in the connecting cleft of the binding pockets (Figs. 1B and 1C) , which are known to enhance the binding affinity against fatty acids.
14 The length of the peptide linker with an extended conformation is 2.4 nm, which will be enough to crosslink the hydrophobic pockets. Peptide 2 is a control peptide possessing one alkyl group. Peptide 4 is another control peptide, whose linker includes flexible oligoethyelene glycol units with two-times longer length than that of all other peptides.
To evaluate the binding of the synthesized peptides to HSA, we utilized a competitive replacement with ANS. ANS is basically non-fluorescent in aqueous media but shows strong fluorescence upon binding to the hydrophobic pocket of HSA. [15] [16] [17] Thus, the replacement of ANS bound to HSA with ligands causes quenching of the ANS fluorescence. It has been reported that subdomain IIIA and IIA of HSA have the binding pockets of ANS to provide fluorescent property to ANS. 18, 19 Therefore, the fluorescence quenching is caused mainly by the competition with the ANS bound to the IIIA/IIA subdomain. Figure 3A shows results of competitive titration of ANS/HSA complex with the peptides or myristic acid. Figure 3A (1)
in which η and Kd(rel) are the replaced fraction of ANS and the relative dissociation constant of each ligand against ANS, respectively. The absolute Kd value of each ligand were calculated from the Eq. (2), in which Kd(ANS) was determined experimentally by titration of HSA solution with ANS to be 2.7 × 10 -7 M. As shown in Figs. 3A and 3B, myristic acid almost completely replaced ANS bound to HSA and its Kd is calculated to be 1.7 × 10 -7 M, which is in agreement with reported values. 21 Peptide 2, which has a single alkyl group, was found to have Kd of 8.9 × 10 -6 and induced only ca. 30% quenching of ANS even at its maximum concentration (200 μM). The weak binding affinity of peptide 2 is probably due to the solubility increase of the alkyl group resulted from the modification of hydrophilic linker or the steric hindrance caused by the linker. Kd value of dual alkylated peptides 1 and 3 greatly improved the binding affinity to HSA, which are calculated to be 4.0 × 10 -8 M and 1.4 × 10 -7 M, respectively. The improved binding affinity of peptide 1 and 3 will be explained by their simultaneous binding to two pockets of HSA. It is interesting to note that the quenching of ANS by 1 and 3 was saturated around 60%. Reported numbers of bound ANS to the HSA subdomain IIIA and IIA are one and two, respectively. 18, 22 Assuming that the quantum yields of these three ANSs are equivalent, 60% quenching shows the dissociation of two out of the three bound ANSs from HSA. The binding of peptide 1 and 3 to the pockets of 4 and 5 results in dissociation of only one ANS at IIIA, which cannot explain the 60% quenching. While the binding of the peptides to the pockets 4 and 6 results in the dissociation of one ANS in IIIA and one of two ANSs in IIA, which is matched with 60% quenching. Thus, peptides 1 and 3 will specifically bind to pocket 4 and 6. Incomplete quenching by peptides 1 and 3 shows that their binding affinity to the other pocket in IIA domain is not enough to replace the remaining ANS. It is a sharp contrast with the simple fatty acids like myristic acid, which can replace all the three fluorescent ANSs. We concluded that peptides 1 and 3 gained specificity in the binding pockets.
Despite having a longer alkyl chain (C16), peptide 3 showed a similar binding affinity towards HSA with that of the peptide 1 (C14). This result is in agreement with previous results that the binding affinity of alkyl group to HSA does not increase when its length is more than 14 carbon atoms. 10 As in the case of peptide 4, its flexible and two-times longer spacer completely spoiled its binding affinity towards HSA, indicating that designing the linker being complementary to the cleft connecting the pockets is crucial to the high binding affinity of the peptides to HSA.
Finally, we examined the retention ability of peptides 1 and 2 in the blood circulation of mice. Here, we used peptides 1-Cy7 and 2-Cy7, in which Cy7 fluorophore was modified on their N-terminus. Each peptide (2.1 nmol) was intravenously injected through the tail vein. Blood samples were collected at 6 h postinjection to measure the remaining peptides in plasma. As shown in Fig. 4 , 80% of dual alkylated 1-Cy7 was retained in the blood circulation, which was about 3-fold higher than that of the single alkylated 2-Cy7. This result corresponds to a stronger binding of 1-Cy7 to mouse serum albumin. No crystal structure of mouse serum albumin has so far been reported. However, based on amino acid sequential studies, important residues for the binding of fatty acids are nearly completely conserved among all species. Thus, we can expect a similar binding behavior from human serum albumin and mouse serum albumin. 23 
Conclusions
In conclusion, we have proposed a new peptide design, dual alkylated peptides 1 and 3, with an improved binding affinity to HSA. By a competitive binding technique, peptides 1 and 3 were found to share the HSA's binding pockets 4 and 6 for fatty acids, with a significantly higher binding affinity than the single alkylated peptide 2. The in vivo experiment showed an improved retention of peptide 1 compared with 2 in blood circulation. Therefore, we believe that our design of HSA binding ligands is promising to improve not only the bioavailability of peptide drugs, but also molecular probes for cancer imaging, which will result in the reduction of their dosage frequency and side effects.
Supporting Information
Additional result regarding the effect of peptide ligand on the fluorescence of ANS is available free of charge on the Web at http://www.jsac.or.jp/analsci/.
